| Year |
Citation |
Score |
| 2024 |
Rivas S, Sepúlveda RV, Tapia I, Estay C, Soto V, Blanco A, González E, Armisen R. MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients. International Journal of Molecular Sciences. 25. PMID 39769478 DOI: 10.3390/ijms252413715 |
0.659 |
|
| 2024 |
Bernal YA, Blanco A, Oróstica K, Delgado I, Armisén R. Integration of RNA Editing with Multiomics Data Improves Machine Learning Models for Predicting Drug Responses in Breast Cancer Patients. Research Square. PMID 39764127 DOI: 10.21203/rs.3.rs-5604105/v1 |
0.656 |
|
| 2024 |
Garrido J, Bernal Y, González E, Blanco A, Sepúlveda-Hermosilla G, Freire M, Oróstica K, Rivas S, Marcelain K, Owen G, Ibañez C, Corvalan A, Garrido M, Assar R, Lizana R, et al. Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers. Bmc Cancer. 24: 951. PMID 39097719 DOI: 10.1186/s12885-024-12737-1 |
0.599 |
|
| 2024 |
Tapia-Valladares C, Valenzuela G, González E, Maureira I, Toro J, Freire M, Sepúlveda-Hermosilla G, Ampuero D, Blanco A, Gallegos I, Morales F, Erices JI, Barajas O, Ahumada M, Contreras HR, et al. Distinct Driver Pathway Enrichments and a High Prevalence of Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis. International Journal of Molecular Sciences. 25. PMID 38731914 DOI: 10.3390/ijms25094695 |
0.6 |
|
| 2024 |
Bernal YA, Blanco A, Sagredo EA, Oróstica K, Alfaro I, Marcelain K, Armisén R. A Comprehensive Analysis of the Effect of A>I(G) RNA-Editing Sites on Genotoxic Drug Response and Progression in Breast Cancer. Biomedicines. 12. PMID 38672084 DOI: 10.3390/biomedicines12040728 |
0.683 |
|
| 2023 |
Arratia F, Fierro C, Blanco A, Fuentes S, Nahuelquen D, Montecino M, Rojas A, Aguilar R. Selective Concurrence of the Long Non-Coding RNA MALAT1 and the Polycomb Repressive Complex 2 to Promoter Regions of Active Genes in MCF7 Breast Cancer Cells. Current Issues in Molecular Biology. 45: 4735-4748. PMID 37367050 DOI: 10.3390/cimb45060301 |
0.418 |
|
| 2021 |
Sepúlveda-Hermosilla G, Freire M, Blanco A, Cáceres J, Lizana R, Ramos L, Assar R, Ampuero D, Aren O, Chernilo S, Spencer ML, Bernal G, Flores J, Rasse G, Sánchez C, et al. Concordance analysis of ALK gene fusion detection methods in patients with Non-Small-Cell Lung Cancer from Chile, Brazil, and Peru. The Journal of Molecular Diagnostics : Jmd. PMID 34186175 DOI: 10.1016/j.jmoldx.2021.05.018 |
0.616 |
|
| 2020 |
de Santiago PR, Blanco A, Morales F, Marcelain K, Harismendy O, Herrera MS, Armisén R. Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis. Life Sciences. 118956. PMID 33383047 DOI: 10.1016/j.lfs.2020.118956 |
0.684 |
|
| 2020 |
Sagredo EA, Sagredo AI, Blanco A, De Santiago PR, Rivas S, Assar R, Pérez P, Marcelain K, Armisén R. ADAR1 Transcriptome editing promotes breast cancer progression through the regulation of cell cycle and DNA damage response. Biochimica Et Biophysica Acta. Molecular Cell Research. 118716. PMID 32275931 DOI: 10.1016/J.Bbamcr.2020.118716 |
0.668 |
|
| 2018 |
Sagredo EA, Blanco A, Sagredo AI, Pérez P, Sepúlveda-Hermosilla G, Morales F, Müller B, Verdugo R, Marcelain K, Harismendy O, Armisén R. ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biological Research. 51: 36. PMID 30290838 DOI: 10.1186/S40659-018-0185-4 |
0.675 |
|
| Show low-probability matches. |